Mode
Text Size
Log in / Sign up

CareAide mHealth application improves medication adherence and quality of life in type 2 diabetesPharmacist-led mobile app improves medication habits for type 2 diabetes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider CareAide mHealth apps to improve medication adherence and quality of life in type 2 diabetes patients.

This multicentre randomized controlled trial enrolled 663 patients with type 2 diabetes across three Malaysian hospitals. Participants were evaluated over a 6-month follow-up period to assess the impact of CareAide, a pharmacist-driven mHealth application, on medication adherence, health-related quality of life (HRQoL), and glycaemic control.

CareAide significantly improved medication adherence, with MMAS-8 scores of 7.31 versus 5.55 (p < 0.001) and a Proportion of Days Covered (PDC) of 81.6% versus 33.0% (p < 0.001). Quality of life scores also improved, with AQoL-6D utility reaching 0.669 versus 0.618 (p < 0.001).

Glycaemic outcomes were mixed. A baseline-adjusted ANCOVA showed an HbA1c reduction of 0.41% (p = 0.002), but the SEM model and complete-case comparison did not reach statistical significance (p = 0.065 and p = 0.153, respectively).

Safety data were not reported. The study noted that HRQoL improvements were independent of medication adherence. Clinical application is limited by incomplete HbA1c data at one site, requiring confirmation in longer studies with more complete data.

How this fits prior evidence

This finding addresses a gap in non-pharmacological management for type 2 diabetes. While prior evidence has established the efficacy of SGLT2 inhibitors for glycemic control and weight loss, and identified biomarkers like NT-proBNP for predicting outcomes, this study evaluates a digital intervention to improve adherence and quality of life. The study confirms that pharmacist-driven mHealth tools can improve patient behavior, though the impact on HbA1c requires more robust data to confirm the findings seen in the baseline-adjusted ANCOVA.

Managing type 2 diabetes is a daily challenge that requires consistent medication habits. For many, simply remembering to take the right pills at the right time is a hurdle that can impact long-term health. A study involving 663 patients in Malaysia looked at how a pharmacist-led mobile app, called CareAide, could help patients stay on track.

The results showed that patients using the app were much more likely to take their medicine correctly. Specifically, the group using the app had a much higher rate of staying on their medication schedule compared to the group that did not. These patients also reported a better quality of life. The study found that the first three months of pharmacist support were the most critical time for making these positive changes.

While the app helped people stick to their routines, the results regarding blood sugar levels, known as HbA1c, were more complex. While some data showed a small drop in blood sugar, other parts of the study did not show a statistically significant change. Because some data was missing from one location, researchers suggest that longer studies are needed to confirm how much the app affects blood sugar levels over time.

What this means for you:
A pharmacist-led mobile app significantly improves medication habits and quality of life for people with type 2 diabetes.

Common questions

How does this app help people with type 2 diabetes?

The CareAide app is a pharmacist-driven mobile tool. It helps patients stay consistent with their medications and improves their overall quality of life. The study found that the first three months of using this pharmacist-led support are the most critical period for improving these habits.

Did the app improve blood sugar levels?

The results for blood sugar, measured as HbA1c, were mixed. While one calculation showed a reduction of 0.41%, other tests did not show a statistically significant change. Because some data was missing from one site, more long-term studies are needed to confirm the impact on blood sugar.

How much did it improve medication habits?

The app showed a significant improvement in medication habits. Specifically, 81.6% of the users met the goal of being on their medication for at least 80% of the time, compared to only 33.0% of those not using the app.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up6.0 mo
PublishedSep 2026
View Original Abstract ↓
AIMS: To evaluate whether CareAide®, a pharmacist-driven mHealth application, improves medication adherence, health-related quality of life (HRQoL), and glycaemic control in diabetes mellitus using structural equation modelling. METHODS: Pre-specified secondary analysis of the type 2 diabetes mellitus cohort from a 6-month multicentre open-label randomised controlled trial (N = 663) across three Malaysian hospitals. Adherence was assessed by MMAS-8 (subjective) and Proportion of Days Covered (PDC; pharmacy-verified). HRQoL was measured by AQoL-6D and EQ-5D-5 L. Structural equation modelling (SEM), Necessary Condition Analysis, and Importance-Performance Map Analysis (cIPMA) were applied. RESULTS: CareAide® produced large adherence gains (MMAS-8: 7.31 vs 5.55, d = 1.64; PDC ≥ 80%: 81.6% vs 33.0%; both p < 0.001). Early 3-month adherence was the strongest predictor of sustained 6-month adherence in both models (β std = 0.567 and 0.688; p < 0.001). AQoL-6D utility improved significantly (0.669 vs 0.618; d = 0.353, p < 0.001), driven by coping (d = 0.447) and relationships (d = 0.254) domains. HRQoL did not mediate adherence; gains were a direct independent benefit. The intervention effect on HbA1c was not statistically significant in the PDC-based SEM model (β =  - 0.333, p = 0.065); a group difference was, however, supported by baseline-adjusted ANCOVA (β =  - 0.41%, p = 0.002), and the complete-case comparison was non-significant (p = 0.153), so glycaemic findings warrant cautious interpretation. cIPMA identified the intervention as the primary optimisation target. CONCLUSIONS: CareAide® significantly improves medication adherence and psychosocial quality of life. Evidence for glycaemic benefit came from baseline-adjusted analysis (ANCOVA), though findings should be interpreted with caution given incomplete HbA1c data at one site. The first three months are the most critical period for pharmacist support. In this dataset, PDC appeared more sensitive than MMAS-8 to the HbA1c signal within 6 months, but this finding requires confirmation in longer studies with more complete HbA1c data. TRIAL REGISTRATION: ClinicalTrials.gov NCT06068309.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.